Press releases, Reports & Disclosures for Gulf Pharmaceutical Industries

Gulf Pharmaceutical Industries P.S.C. has released its unaudited interim condensed consolidated financial statements for the period ending 30 June 2024.

Resolution No. 465 of 2024 announces the temporary suspension of trading for Gulf Pharmaceutical Industries (JULPHAR) shares on the Abu Dhabi Securities Exchange (ADX). This suspension will start at 12:00 PM on August 14, 2024, due to a Board of Directors meeting that coincides with the trading session. Trading will resume once ADX receives the meeting results. The resolution requires all ADX department heads to implement this decision and mandates its circulation to the Securities and Commodities Authority (SCA), the concerned company, relevant ADX departments, and accredited brokers. The resolution was approved by the authorized person and issued on August 8, 2024.

The document in question is an unaudited interim condensed consolidated financial statement from Gulf Pharmaceutical Industries P.S.C., as of 31 March 2024. This is a financial report that provides an overview of the company's economic status and performance during this period.

Resolution No. 402 of 2024 pertains to the temporary suspension of trading on the shares of Gulf Pharmaceutical Industries. The resolution is in accordance with Article No. 16 of the Regulations concerning the listing of securities on ADX. As per the resolution, trading on JULPHAR shares will be suspended from 09:00 on 14-May-2024 until ADX receives the meeting results of the Gulf Pharmaceutical Industries Board of Directors meeting scheduled at 11:00 on the same day. The resolution instructs all department heads at ADX to execute this decision and circulate the information to SCA, the concerned company, all departments at ADX, and all brokers accredited by ADX. The resolution was issued on 09/05/2024 and has been approved by an authorised person.